Yes, on average — but “how much” depends heavily on which study you’re reading, and the studies don’t agree. A 2024 systematic review specifically on semaglutide found lean mass accounted for anywhere from almost 0% to 40% of total weight lost across the trials it reviewed. A newer 12-month study found something most coverage of this topic doesn’t mention at all: strength went up, not down, even as fat loss continued.
What “muscle loss” actually means in these studies
Almost every number you’ll read about Wegovy and muscle comes from a DXA scan — the same dual-energy X-ray scan used to measure bone density, adapted to also estimate body composition. DXA doesn’t measure muscle fibers directly. It measures “lean mass,” a category that includes muscle but also organs, water, and connective tissue. A drop in lean mass on a DXA scan is a reasonable proxy for muscle trends, and it’s what the research actually has to work with, but it’s worth knowing it’s not a pure muscle measurement before treating any single percentage as exact.
This matters practically because DXA is a middle-ground tool, not the most precise one available. Simple bioelectrical-impedance scales (the kind built into some bathroom scales) are less reliable than DXA for tracking body composition changes over time; MRI can isolate actual skeletal muscle volume more precisely than DXA can, but it’s expensive and impractical for a trial with over a hundred participants. DXA is the standard in this research because it’s the reasonable middle option, not because it’s the last word on what’s happening to muscle specifically.
Why a calorie deficit costs lean mass at all
None of this is unique to Wegovy or to GLP-1 medications as a class. Any sufficiently large, sustained calorie deficit — whatever produces it — pushes the body to draw energy from both fat and lean tissue, not fat exclusively. Semaglutide’s role is indirect: it suppresses appetite effectively enough that most people end up in a substantial deficit, often without deliberately dieting at all, and it’s the deficit itself, not anything semaglutide does to muscle tissue directly, that creates the lean-mass risk. This is exactly why the factors that show up across the research below aren’t drug-specific either.
Why the number you read keeps changing
A 2024 systematic review published in Expert Opinion on Pharmacotherapy, looking specifically at semaglutide’s effect on lean mass across clinical trials, found reductions “ranging from almost 0% to 40% of total weight reduction” — the review’s own words, not a rounded summary. That’s not a typo or inconsistent reporting; it reflects real differences between the trials themselves. A separate 2024 network meta-analysis across the broader GLP-1 drug class (not semaglutide alone) put the pooled average nearer 25% — a useful middle reference point, but still an average sitting inside that much wider 0-40% range, not a replacement for it.
A few things reliably move a given trial’s number, and none of them are the drug dose itself:
- How long the trial ran. A 12-week trial and a 68-week trial are measuring different phases of the same process, and lean mass doesn’t necessarily decline at a constant rate throughout.
- How much protein participants were actually eating. Trials rarely control this tightly, and protein intake is one of the best-documented levers for how much of a deficit’s weight loss comes from lean tissue versus fat.
- Whether resistance training was part of the protocol. Some trials include it as standard care; others don’t track it at all.
- Age and baseline muscle mass. Older participants and those starting with less muscle reserve generally show larger relative lean-mass changes for the same absolute loss.
- How heavy participants were at baseline. People starting at a higher body weight typically have more lean mass in absolute terms to begin with, which changes what a given percentage represents.
Practically, this means a single “Wegovy causes X% muscle loss” headline is always going to be true of some study and false of others. The honest answer is a range shaped by these factors, not one fixed number.
A 12-month study most coverage doesn’t mention
The SEMALEAN study, published in Diabetes, Obesity and Metabolism in early 2026, followed 106 adults with severe obesity (mean BMI 46.3) on semaglutide for a full 12 months — longer than most of the trials behind the muscle-loss headlines, which typically run under a year. Fat mass dropped steadily throughout (−14.3% at 7 months, −18.9% at 12 months). Lean mass told a different story: it dropped by about 3kg by month 7, then stabilized rather than continuing to decline through month 12. Handgrip strength — a direct physical measurement, not a DXA estimate — actually increased, by 3.7kg at 7 months and 4.1kg at 12 months. The share of participants meeting criteria for sarcopenic obesity (low muscle function alongside excess fat) fell from 49% at the start of the study to 33% at the end.
This is one study, and it doesn’t cancel out the trials showing real lean-mass loss elsewhere. Its population matters too: 106 completers, average age 52, about 69% female, and a starting BMI (46.3) high enough that most participants would be considered candidates for bariatric surgery — a notably different group than a general Wegovy user closer to the drug’s typical eligibility threshold. Whether the same stabilization and strength pattern holds for someone starting at a lower weight, or younger, isn’t something this study can answer on its own. But it’s hard to find mentioned in most existing coverage of “Wegovy muscle loss,” and it directly complicates the assumption that muscle loss on semaglutide is a straight line that only gets worse the longer you stay on it.
The numbers side by side
| Semaglutide systematic review (2024) | SEMALEAN study (2026) | |
|---|---|---|
| Duration covered | Multiple trials, varying lengths | 12 months, single trial |
| Lean mass as % of weight lost | Range: ~0% to 40% | Declined then stabilized after month 7 |
| Strength measured directly | Not part of this review | Handgrip +4.1kg by month 12 |
| Sarcopenic obesity prevalence | Not assessed | 49% → 33% |
So should you be worried?
Somewhere between “this is nothing to think about” and “this is inevitable and severe” — neither extreme matches what the actual research shows. Some lean mass loss during a large, sustained calorie deficit is normal and expected, semaglutide or otherwise; that’s how energy deficits work on any body. The size of that loss varies a lot by individual and by how the deficit is managed, and newer, longer-duration data suggests it isn’t necessarily a one-way slide the longer treatment continues. The two factors that show up consistently across this research as the ones you can actually influence are protein intake and resistance training — not the drug dose, and not how long you’ve been on it.
What actually helps
This site has a full breakdown of the protein side specifically — how much protein you need on GLP-1 medications covers the actual gram target research supports and practical ways to hit it when appetite suppression makes eating enough genuinely difficult, which is worth reading in full rather than repeating here. If you already know your numbers, the protein calculator applies that same range directly to your own bodyweight. The short version: protein intake and resistance training are the two levers every study in this piece points back to, regardless of which lean-mass percentage that particular study happened to find.
Muscle preservation matters through the whole arc of treatment, not just while you’re actively losing weight. If you’re approaching the end of treatment or thinking about tapering off, weight regain after stopping GLP-1 medications covers what changes — including how to recalculate your calorie and protein targets before appetite fully returns, rather than protecting muscle during treatment only to lose ground right after.